UNLIMITED FREE
ACCESS
TO THE WORLD'S BEST IDEAS

SUBMIT
Already a GlobalSpec user? Log in.

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

Customize Your GlobalSpec Experience

Finish!
Privacy Policy

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

ASTM International - ASTM E3411-24

Standard Practice for Validation of Automated Membrane Microscopy Test Methods for the Counting and Sizing of Particulate Matter Present in Parenteral Pharmaceutical Manufacturing Processes and Final Drug Products

active
Buy Now
Organization: ASTM International
Publication Date: 1 November 2024
Status: active
Page Count: 10
ICS Code (Particle size analysis. Sieving): 19.120
significance And Use:

4.1 From a quality risk management perspective (ICH Q9), extraneous solid and insoluble particulate matter in a final parenteral drug product is a potential hazard that may cause harm to the... View More

scope:

1.1 This practice covers the requirements for validation of test methods that apply automated membrane microscopy (AMM) to the measurement of extraneous solid insoluble particulate matter present in parenteral pharmaceutical manufacturing processes and drug products. For extensive guidance on the development of AMM test methods see Guide E3425.

1.2 In an AMM test method, a test liquid containing suspended particles is filtered through a membrane filter, the particles are retained on the surface of the membrane filter, the membrane filter surface is imaged with an optical microscope and digital camera, and application of image analysis software determines particle count and particle sizes.

1.3 AMM test methods may be applied to the measurement of the commonly defined size categories of subvisible (<100?μm) or visible (=100?μm) or both particulate matter present during any stage of the manufacturing of parenteral pharmaceuticals.

1.4 The test liquid characterized by an AMM test method may be a process fluid, drug substance or drug product, or liquid extracts from the surfaces of processing equipment, drug containers, delivery devices, and components thereof.

1.5 This practice does not apply to the characterization of particles inherent to parenteral suspensions (for example, cells, protein aggregates, or vaccine adjuvants) or the characterization of liquid droplets (for example, silicone oil).

1.6 Units-The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.

1.7 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.

1.8 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

Document History

ASTM E3411-24
November 1, 2024
Standard Practice for Validation of Automated Membrane Microscopy Test Methods for the Counting and Sizing of Particulate Matter Present in Parenteral Pharmaceutical Manufacturing Processes and Final Drug Products
4.1 From a quality risk management perspective (ICH Q9), extraneous solid and insoluble particulate matter in a final parenteral drug product is a potential hazard that may cause harm to the patient...
Advertisement